Prospects for Bayer's oral Factor XIa inhibitor asundexian were looking speculative when it failed a phase 3 trial in atrial fibrillation (AF), but new data in secondary stroke prevention could get ...
In the heart of the nation's capital, in a courthouse of the U.S. government, one man will stop at nothing to keep his honor, and one will stop at nothing to find the truth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback